Inventor · disambiguated record
Zhi-Fu Tao
Also filed as: TAO ZHI-FU
47 granted patents·52 pending applications·709 citations·filing 1999–2024
98Inventor score
Top patents by PatentIndex Score
99 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0297US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0397US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0497US8580794B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Nov 12, 2013·44 cites·3 claims
- 0597US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 0697US8557983B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Oct 15, 2013·44 cites·2 claims
- 0796US9034875B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 19, 2015·19 cites·1 claims
- 0896US9029404B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 12, 2015·19 cites·1 claims
- 0994US9315488B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2015·Granted Apr 19, 2016·13 cites·2 claims
- 1094US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 1194US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 1294US9045475B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·14 cites·2 claims
- 1394US8952157B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Feb 10, 2015·22 cites·5 claims
- 1494US8426422B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesHEXAMER LAURA A·Filed 2010·Granted Apr 23, 2013·49 cites·4 claims
- 1593US8883784B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 11, 2014·11 cites·14 claims
- 1692US9403822B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Aug 2, 2016·9 cites·6 claims
- 1792US8940737B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Jan 27, 2015·7 cites·10 claims
- 1892US8232273B2Heterocyclic compounds and methods of useBAELL JONATHAN BAYLDON·Filed 2009·Granted Jul 31, 2012·28 cites·31 claims
- 1991US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 2090US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 2189US10676485B2Macrocyclic MCL-1 inhibitors and methods of useABBVIE INC·Filed 2018·Granted Jun 9, 2020·2 cites·2 claims
- 2289US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 2388US8889675B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2012·Granted Nov 18, 2014·3 cites·9 claims
- 2487US9006247B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesTAO ZHI-FU·Filed 2011·Granted Apr 14, 2015·11 cites·5 claims
- 2587US8148384B2Substituted thieno[3,2-d]pyrimidine PIM kinase inhibitors as cancer chemotherapeuticsPENNING THOMAS D·Filed 2007·Granted Apr 3, 2012·6 cites·8 claims
- 2687US7981888B21-oxyalkyl-2-carboxyl-7-nonsubstituted indole derivativesABBOTT LAB·Filed 2008·Granted Jul 19, 2011·8 cites·7 claims
- 2787US2024285611A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 2886US9266877B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Feb 23, 2016·2 cites·2 claims
- 2986US9227963B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Jan 5, 2016·2 cites·2 claims
- 3086US2025313572A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3186US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 3284US2025177374A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2024·Application pending·0 cites
- 3383US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 3482US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 3582US6566336B1Compounds alkylating specific base sequence of DNA and method for synthesizing the sameJAPAN SCIENCE & TECH CORP·Filed 1999·Granted May 20, 2003·48 cites·9 claims
- 3682US2024228509A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2023·Application pending·0 cites
- 3781US7956185B2Cyclobut-3-ene-1,2,-dione inhibitors of polo-like kinasesABBOTT LAB·Filed 2007·Granted Jun 7, 2011·5 cites·5 claims
- 3881US2025092062A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2024·Application pending·0 cites
- 3980US8445679B27-substituted indole MCL-1 inhibitorsWANG XILU·Filed 2008·Granted May 21, 2013·7 cites·4 claims
- 4078US8969375B2CDK9 kinase inhibitorsABBVIE INC·Filed 2014·Granted Mar 3, 2015·2 cites·17 claims
- 4178US2023399340A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4277US9877958B2Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Granted Jan 30, 2018·1 cites·16 claims
- 4377US9844547B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Granted Dec 19, 2017·1 cites·10 claims
- 4477US2024058450A1BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the SameABBVIE INC·Filed 2022·Application pending·0 cites
- 4577US2022259226A1Macrocyclic mcl-1 inhibitors and methods of useABBVIE INC·Filed 2022·Application pending·0 cites
- 4676US9650358B2Pyridine CDK9 kinase inhibitorsABBVIE INC·Filed 2014·Granted May 16, 2017·1 cites·18 claims
- 4776US9035047B27-substituted indole Mcl-1 inhibitorsABBVIE INC·Filed 2013·Granted May 19, 2015·1 cites·4 claims
- 4875US2020277291A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 4975US2023183261A1Macrocyclic MCL-1 Inhibitors and Methods of UseABBVIE INC·Filed 2022·Application pending·0 cites
- 5075US2022315555A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 99 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →